Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605528 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL20046181 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL29547640 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL31589236 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL31605512 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL31589896 | 0.91 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL21982902 | 0.85 | CRBN (0.54) | CRBNDDB1BACE1PDK2MAPT | |
| SCHEMBL31236676 | 0.85 | CRBN (0.64) | CRBNDDB1 | |
| SCHEMBL31620797 | 0.83 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL31491162 | 0.83 | CRBN (0.60) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | ARVINAS OPERATIONS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043612-B2 | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same | PAICS, UGT1A1, PBRM1 | CRBN 1606/4885DDB1 2095/4885BACE1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.